Journal of Cancer Immunology & Therapy

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (202) 780-3397

Short Communication - Journal of Cancer Immunology & Therapy (2023) Volume 6, Issue 4

Development of Tumor Microenvironments in Human body

Emma Munkley *

Department of Hematology

*Corresponding Author:
Emma Munkley
Department of Hematology
University of Newcastle
United Kingdom

Received:26-Jul-2023,Manuscript No. AAJCIT-23-109861; Editor assigned: 28-Jul-2023, PreQC No. AAJCIT-23-109861 (PQ); Reviewed:11-Aug -2023, QC No. AAJCIT-23-109861; Revised:16-Aug -2023, Manuscript No. AAJCIT-23-109861 (R); Published:23-Aug -2023, DOI: 10.35841/aajcit- 6.4.161

Citation: Munkley E, Development of tumor microenvironments in human body. J Cancer Immunol Ther. 2023; 6(4):161

Visit for more related articles at Journal of Cancer Immunology & Therapy




Cancer, a multifaceted and devastating disease, continues to be a significant global health challenge. Over the years, strides have been made in cancer research and treatment modalities, leading to improved patient outcomes. One of the most promising frontiers in the battle against cancer is the field of Cancer Immunology & Therapy, which aims to harness the body's own immune system to recognize and eliminate cancer cells. The integration of immunotherapy with our understanding of the tumor microenvironment has emerged as a game-changing approach, offering new avenues for precise and targeted interventions. Immunotherapy operates on the principle that the immune system can be mobilized to recognize and destroy cancer cells effectively. However, tumor cells often develop ingenious strategies to evade immune surveillance, allowing them to thrive and proliferate. Herein lies the importance of the tumor microenvironment, a complex ecosystem surrounding the tumor, consisting of various cell types, soluble factors, and the extracellular matrix. This microenvironment plays a crucial role in tumor growth, progression, and response to therapy, and has become a focal point of research in recent years [1].

The tumor microenvironment can be both friend and foe. On the one hand, it provides crucial support for tumor cells, facilitating their growth and dissemination. Immune cells within the tumor microenvironment can be reprogrammed or inhibited by the tumor, rendering them less effective in detecting and destroying cancer cells. Moreover, the presence of immunosuppressive factors, such as regulatory T cells and myeloid-derived suppressor cells, can dampen the immune response and promote tumor immune evasion. Additionally, the extracellular matrix and associated signaling molecules create physical and biochemical barriers that limit the penetration and effectiveness of immune cells within the tumor mass. On the other hand, the tumor microenvironment also presents an array of potential therapeutic targets for cancer immunotherapy. Researchers have identified specific immune checkpoints, such as programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), that act as brakes on the immune system. By blocking these checkpoints with immune checkpoint inhibitors, such as pembrolizumab and ipilimumab, the anti-tumor immune response can be reinvigorated, leading to impressive clinical responses in a subset of patients across various cancer types [2].

Furthermore, ongoing research is exploring novel strategies to modify the tumor microenvironment to promote a more favorable immune response. These approaches include targeting cytokines and chemokines that promote immunosuppression, depleting immunosuppressive cell populations, and enhancing the infiltration and function of effector immune cells.In this article, we will delve deeper into the intricate interplay between cancer immunology, therapy, and the tumor microenvironment [3]. 

We will explore recent advancements in our understanding of immune escape mechanisms employed by cancer cells and how these insights are being translated into innovative immunotherapeutic strategies. Additionally, we will examine the challenges faced in harnessing the full potential of the tumor microenvironment for cancer treatment and the ongoing efforts to overcome these obstacles. Cancer Immunology & Therapy, when combined with insights into the tumor microenvironment, has ushered in a new era of personalized and targeted cancer treatment. As research continues to unravel the mysteries of this intricate landscape, the potential for transformative therapies that offer lasting remissions and improved quality of life for cancer patients becomes ever more promising [4,5].


In recent years, cancer immunology and therapy have emerged as groundbreaking fields in cancer research, revolutionizing the way we understand and treat this complex disease. One of the most significant advancements in this area is the recognition of the critical role played by the tumor microenvironment (TME) in cancer progression and response to treatment. The TME is a dynamic ecosystem consisting of various cell types, signaling molecules, and extracellular matrix components surrounding the tumor. Understanding and harnessing the intricate interplay within the TME hold immense promise in the quest for effective cancer therapies. Research has unveiled the multifaceted interactions between cancer cells and the TME. Cancer cells can manipulate the TME to create a favorable environment for their survival and proliferation. One such strategy involves evading immune surveillance by suppressing the immune system's ability to recognize and eliminate cancer cells. Immune checkpoints, regulatory molecules that maintain self-tolerance and prevent autoimmunity, are co-opted by cancer cells to dampen the immune response.


  1. LeBleu V.Imaging the tumor microenvironment. Cancer J. 2015;21:174–78.
  2. Indexed at, Google Scholar, Cross Ref

  3. Korneev K.V, Atretkhany K.N, Drutskaya M.S, et al.TLR-signaling and proinflammatory cytokines as drivers of tumorigenesis. Cytokine. 2017;89:127–35.
  4. Indexed at, Google Scholar,Cross Ref

  5. Feig C.. Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancer. Proc Natl Acad Sci. USA. 2013;110:20212–17.
  6. Indexed at, Google Scholar, Cross Ref

  7. Chen F.New horizons in tumor microenvironment biology: Challenges and opportunities. BMC Med. 2015;13:45.
  8. Indexed at, Google Scholar, Cross Ref

  9. Pylayeva-Gupta Y.Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia Cancer Cell. 2012;21:836–47.
  10. Indexed at, Google Scholar, Cross Ref

Get the App